JP5491040B2 - Tablets containing acarbose - Google Patents
Tablets containing acarbose Download PDFInfo
- Publication number
- JP5491040B2 JP5491040B2 JP2009033818A JP2009033818A JP5491040B2 JP 5491040 B2 JP5491040 B2 JP 5491040B2 JP 2009033818 A JP2009033818 A JP 2009033818A JP 2009033818 A JP2009033818 A JP 2009033818A JP 5491040 B2 JP5491040 B2 JP 5491040B2
- Authority
- JP
- Japan
- Prior art keywords
- acarbose
- tablet
- surface area
- specific surface
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 title claims description 40
- 229960002632 acarbose Drugs 0.000 title claims description 40
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 title claims description 40
- 239000003463 adsorbent Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 17
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000012239 silicon dioxide Nutrition 0.000 claims description 12
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 8
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 238000013329 compounding Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 51
- 238000000034 method Methods 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- -1 sucrose fatty acid ester Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 235000010724 Wisteria floribunda Nutrition 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229950008138 carmellose Drugs 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Description
本発明は、食後過血糖改善剤であるアカルボースを含有する錠剤に関するものである。 The present invention relates to a tablet containing acarbose which is a postprandial hyperglycemia improving agent.
アカルボースは腸管内において炭水化物の消化・吸収に関与するα−アミラーゼ及びα−グルコシダーゼ(スクラーゼ,マルターゼ等)の活性を阻害することにより食後の血糖上昇を抑制する作用を有しており、食後過血糖を改善する目的で用いられている。 Acarbose has the effect of suppressing postprandial blood glucose increase by inhibiting the activities of α-amylase and α-glucosidase (such as sucrase and maltase) involved in carbohydrate digestion and absorption in the intestinal tract. It is used for the purpose of improving.
アカルボース原薬は吸湿性が強いことが知られており、吸湿すると含量低下、変色を起こし取扱いが大変困難であった。そこで、特開昭58−46013号公報では、アカルボースなどのグリコシド水解酵素抑制剤に殿粉並びにステアリン酸マグネシウム等を配合し、水分含有量が調製物の6重量%以下とした薬剤調製物とすることによりアカルボースの分解を防止し、保存安定性を改善することが開示されている。 Acarbose drug substance is known to have a strong hygroscopic property, and when it absorbs moisture, its content decreases and discolors, making it very difficult to handle. Therefore, in Japanese Patent Application Laid-Open No. 58-46013, a glycoside hydrolase inhibitor such as acarbose is mixed with starch and magnesium stearate to obtain a pharmaceutical preparation having a water content of 6% by weight or less of the preparation. Therefore, it is disclosed that the decomposition of acarbose is prevented and the storage stability is improved.
しかしながら、上記調製物と同様の処方構成を有する錠剤を20℃、相対湿度75%及び30℃、相対湿度90%の条件下で4週間保存したところ、成分含量に変化はないものの、錠剤の変色が認められたことが報告されている(医学と薬学32(3)597−601,1994)。 However, when the tablets having the same composition as the above preparation were stored for 4 weeks under the conditions of 20 ° C., 75% relative humidity and 30 ° C. and 90% relative humidity, the content of the components did not change, but the discoloration of the tablets Has been reported (medicine and pharmacy 32 (3) 597-601, 1994).
このため、アカルボースを含有する錠剤は、大気中の水分との接触を極力回避しなければならず、保管の際には、医療現場だけでなく、患者にも吸湿に注意するよう指導を行う必要があった。 For this reason, tablets containing acarbose must avoid contact with moisture in the atmosphere as much as possible, and it is necessary to instruct not only the medical site but also the patient to be aware of moisture absorption during storage. was there.
本発明者らは、前記課題を解決するため鋭意検討した結果、アカルボースを特定の吸着剤に吸着することにより、上記目的を達成し得ることを見出した。 As a result of intensive studies to solve the above problems, the present inventors have found that the above object can be achieved by adsorbing acarbose to a specific adsorbent.
すなわち、本発明は(1)比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上にアカルボースを吸着させた組成物を含有することを特徴とする錠剤、(2)比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上と無水リン酸水素カルシウムの混合物にアカルボースを吸着させた組成物を含有することを特徴とする錠剤、(3)比表面積が50m2/g以上である多孔性吸着剤がメタケイ酸アルミン酸マグネシウム、軽質無水ケイ酸、含水二酸化ケイ素およびこれらの混合物から選択される(1)、(2)記載の錠剤、(4)比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上をアカルボース1質量部に対して、0.1〜1質量部の割合で含有する(1)〜(3)のいずれかに記載の錠剤、(5)比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上と無水リン酸水素カルシウムの配合比が、重量比で1:0.1〜1:20である(2)〜(4)記載の錠剤、(6)比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上と無水リン酸水素カルシウムの混合物をアカルボース1質量部に対して、0.3〜2質量部の割合で含有する(2)〜(5)のいずれかに記載の錠剤に関する。 That is, the present invention includes (1) a tablet comprising a composition in which acarbose is adsorbed on one or more porous adsorbents having a specific surface area of 50 m 2 / g or more, (2) ratio A tablet comprising a composition obtained by adsorbing acarbose on a mixture of one or more porous adsorbents having a surface area of 50 m <2> / g or more and anhydrous calcium hydrogen phosphate; (3) specific surface area (1), the tablet according to (2), (4) specific surface area, wherein the porous adsorbent having a mass of 50 m 2 / g or more is selected from magnesium aluminate metasilicate, light anhydrous silicic acid, hydrous silicon dioxide and mixtures thereof In any one of (1)-(3) which contains 1 type, or 2 types or more of the porous adsorbent whose A is 50 m <2> / g or more in the ratio of 0.1-1 mass part with respect to 1 mass part of acarbose. Listed tablets, ( ) The mixing ratio of one or more porous adsorbents having a specific surface area of 50 m 2 / g or more and anhydrous calcium hydrogen phosphate is 1: 0.1 to 1:20 by weight (2) to The tablet according to (4), (6) a mixture of one or more porous adsorbents having a specific surface area of 50 m <2> / g or more and anhydrous calcium hydrogen phosphate with respect to 1 part by mass of acarbose, 0.3 It is related with the tablet in any one of (2)-(5) contained in the ratio of -2 mass parts.
比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上にアカルボースを吸着させた組成物を含有する本発明の錠剤は、製造中におけるケーキングを防止し、さらに高湿度条件下でも錠剤の変色、相互付着、容器への付着が改善され安定である。そのため、保管時に格別の配慮をする必要もない。 The tablet of the present invention containing a composition in which acarbose is adsorbed on one or more porous adsorbents having a specific surface area of 50 m2 / g or more prevents caking during production, and further, under high humidity conditions However, tablet discoloration, mutual adhesion, and container adhesion are improved and stable. Therefore, it is not necessary to give special consideration when storing.
さらに、比表面積が50m2/g以上である多孔性吸着剤の1種又は2種以上と無水リン酸水素カルシウムの混合物にアカルボースを吸着させた組成物を含有する錠剤は、前記混合物中の各成分の混合割合を調節することにより所望の錠剤硬度を得ることができる。このため、分割錠や口腔内崩壊錠などに応用することも可能になる。 Furthermore, a tablet containing a composition in which acarbose is adsorbed to a mixture of one or more porous adsorbents having a specific surface area of 50 m <2> / g or more and anhydrous calcium hydrogen phosphate, each component in the mixture The desired tablet hardness can be obtained by adjusting the mixing ratio. For this reason, it becomes possible to apply to a split tablet or an orally disintegrating tablet.
以下、本発明の実施形態について説明する。 Hereinafter, embodiments of the present invention will be described.
本発明において使用するアカルボースは、公知の方法に従って製造したものを使用してもよい。 The acarbose used in the present invention may be produced according to a known method.
本発明の錠剤中におけるアカルボースの含有量は、錠剤中10〜60重量%、好ましくは20〜50重量%で調製するのがよい。また、本発明の錠剤を食後過血糖改善剤として用いる場合、成人の1日量として、好ましくは150mg〜300mgになるようにアカルボースを配合するのがよい。 The content of acarbose in the tablet of the present invention is 10 to 60% by weight, preferably 20 to 50% by weight in the tablet. Moreover, when using the tablet of this invention as a postprandial hyperglycemia improving agent, it is good to mix | blend acarbose so that it may become preferably 150 mg-300 mg as a daily dose of an adult.
本発明において使用する多孔性吸着剤は、比表面積が50m2/g以上、好ましくは100m2/g以上、より好ましくは193m2/g以上、平均粒子径が0.1〜300μm、好ましくは0.5〜250μm、pHが5.0〜9.0、好ましくは6.0〜8.0の範囲のものであり、上記範囲内に含まれる多孔性吸着剤を1種または2種以上混合してもよい。ここで、比表面積が50m2/g未満の多孔性吸着剤を用いた場合、服用するのに支障がない程の大きさに錠剤を製造しようとすると、アカルボースの吸着が不十分となり、目的の錠剤を得ることができない。また多孔性吸着剤の4%スラリーpHが9.0より大きいグレードを使用した場合には、アカルボースが分解する可能性があるため好ましくない。上記多孔性吸着剤の平均粒子径はレーザー回析式粒度分布計又はコールターカウンター法により測定した値であり、比表面積は窒素ガスを用いたBET法により測定した値である。 The porous adsorbent used in the present invention has a specific surface area of 50 m2 / g or more, preferably 100 m2 / g or more, more preferably 193 m2 / g or more, and an average particle size of 0.1 to 300 μm, preferably 0.5 to 250 μm, pH is 5.0 to 9.0, preferably 6.0 to 8.0, and one or more porous adsorbents included in the above range may be mixed. . Here, when a porous adsorbent having a specific surface area of less than 50 m <2> / g is used, if an attempt is made to produce a tablet having a size that does not hinder taking it, acarbose adsorption becomes insufficient, and the target tablet Can't get. In addition, when a grade in which the 4% slurry pH of the porous adsorbent is larger than 9.0 is used, acarbose may be decomposed, which is not preferable. The average particle diameter of the porous adsorbent is a value measured by a laser diffraction particle size distribution meter or a Coulter counter method, and the specific surface area is a value measured by a BET method using nitrogen gas.
上記多孔性吸着剤は、医薬上許容される物質であれば特に限定されないが、例えばメタケイ酸アルミン酸マグネシウム、軽質無水ケイ酸、含水二酸化ケイ素等が挙げられ、これらは、1種または2種以上混合してもよい。 The porous adsorbent is not particularly limited as long as it is a pharmaceutically acceptable substance. Examples thereof include magnesium aluminate metasilicate, light silicic anhydride, hydrous silicon dioxide, and the like. You may mix.
さらに、本発明は上記多孔性吸着剤と無水リン酸水素カルシウムの混合物にアカルボースを吸着させることによっても湿度に対する安定性を改善することができ、その場合は各成分の混合割合を調節することにより所望の錠剤硬度を得ることができる。 Furthermore, the present invention can also improve the stability against humidity by adsorbing acarbose to the mixture of the porous adsorbent and anhydrous calcium hydrogen phosphate, and in that case, by adjusting the mixing ratio of each component Desired tablet hardness can be obtained.
また本発明は上記多孔性吸着剤又は上記混合物に他の任意の吸着剤を加えることもできる。ここで他の任意の吸着剤とは、医薬上許容される物質であれば特に限定されないが、具体例として結晶セルロース、カルメロースカルシウム、ケイ酸マグネシウム、酸化アルミニウム、炭酸マグネシウム、デキストリン、二酸化ケイ素等が挙げられる。 In the present invention, any other adsorbent can be added to the porous adsorbent or the mixture. Here, the other arbitrary adsorbent is not particularly limited as long as it is a pharmaceutically acceptable substance. Specific examples thereof include crystalline cellulose, carmellose calcium, magnesium silicate, aluminum oxide, magnesium carbonate, dextrin, silicon dioxide and the like. Is mentioned.
本発明において使用する多孔性吸着剤は、アカルボース1質量部に対して、0.1〜1質量部、好ましくは0.2〜0.8質量部の割合で添加される。ここで、添加量が0.1質量部未満であると、湿度に対する安定性が改善されない傾向があり好ましくない。 The porous adsorbent used in the present invention is added at a ratio of 0.1 to 1 part by mass, preferably 0.2 to 0.8 part by mass, with respect to 1 part by mass of acarbose. Here, if the addition amount is less than 0.1 parts by mass, the stability against humidity tends to be not improved, which is not preferable.
本発明において使用する多孔性吸着剤と無水リン酸水素カルシウムの配合比は、重量比で、1:0.1〜1:20、好ましくは1:1〜1:5である。上記の比率の範囲内であれば、湿度に対する安定性を改善させ、錠剤硬度を調整することができる。この混合物はアカルボース1質量部に対して0.3〜2質量部、好ましくは0.4〜1質量部の割合で添加される。ここで、添加量が0.3質量部未満であると、湿度に対する安定性が改善されない傾向があり好ましくない。 The compounding ratio of the porous adsorbent and anhydrous calcium hydrogen phosphate used in the present invention is 1: 0.1 to 1:20, preferably 1: 1 to 1: 5, by weight. If it is in the range of said ratio, stability with respect to humidity can be improved and tablet hardness can be adjusted. This mixture is added in an amount of 0.3 to 2 parts by weight, preferably 0.4 to 1 part by weight, based on 1 part by weight of acarbose. Here, if the addition amount is less than 0.3 parts by mass, the stability against humidity tends to be not improved, which is not preferable.
アカルボースを多孔性吸着剤に吸着させる方法は特に限定されず、慣用の方法によって行うことができる。例えば、流動層造粒機を用いて噴霧・吸着させる方法、練合することで吸着させる方法等が挙げられる。 The method for adsorbing acarbose on the porous adsorbent is not particularly limited, and can be performed by a conventional method. For example, a method of spraying and adsorbing using a fluid bed granulator, a method of adsorbing by kneading, and the like can be mentioned.
流動層造粒機を用いて噴霧・吸着させる方法としては、例えば、流動層造粒機(FL−MINI)に多孔性吸着剤を入れ、流動層造粒機下部から空気を送入し、多孔性吸着剤を浮遊させて流動状態を保ち、これにアカルボースを溶解した溶液をスプレーノズルにより噴霧し、吸着させ、流動層造粒機内で乾燥することにより目的の組成物を得る方法が挙げられる。噴霧・吸着させる時の流動空気の温度は、特に限定されないが、通常50〜80℃であり、好ましくは60〜70℃である。乾燥する時の温度は、特に限定されないが、60〜70℃で乾燥するのが好ましい。また、この方法で用いられる溶媒は、アカルボースを溶解し、多孔性吸着剤を溶解しないものであれば特に限定されないが、水、エタノール又はこれらの1種または2種以上の混合溶媒が好ましい。 As a method of spraying and adsorbing using a fluidized bed granulator, for example, a porous adsorbent is put into a fluidized bed granulator (FL-MINI), air is fed from the lower part of the fluidized bed granulator, There is a method of obtaining a desired composition by suspending the adsorbent adsorbent and maintaining a fluid state, spraying a solution in which acarbose is dissolved thereto with a spray nozzle, adsorbing the solution, and drying in a fluidized bed granulator. Although the temperature of the fluid air at the time of spraying and adsorbing is not particularly limited, it is usually 50 to 80 ° C, preferably 60 to 70 ° C. Although the temperature at the time of drying is not specifically limited, It is preferable to dry at 60-70 degreeC. The solvent used in this method is not particularly limited as long as it dissolves acarbose and does not dissolve the porous adsorbent, but water, ethanol, or a mixed solvent of one or more of these is preferable.
練合することで吸着させる方法としては、例えば、ハイスピードミキサー(LFS−GS−2J)、品川ミキサー(5DM−r)等の通常使用される装置に多孔性吸着剤を入れ、これにアカルボースを溶解した溶液を添加し、これらを練合・吸着することにより目的の組成物を得る方法が挙げられる。この方法で用いられる溶媒は、アカルボースを溶解し、多孔性吸着剤を溶解しないものであれば特に限定されないが、水、エタノール又はこれらの1種または2種以上の混合溶媒が好ましい。また、溶媒の除去は通常の乾燥手段でよく、例えば棚式乾燥機(40C)、流動層乾燥機(MP−01)等が挙げられる。乾燥する時の温度は、特に限定されないが、60〜70℃で乾燥するのが好ましい。 As a method of adsorbing by kneading, for example, a porous adsorbent is put in a commonly used apparatus such as a high speed mixer (LFS-GS-2J), Shinagawa mixer (5DM-r), and acarbose is added thereto. A method of obtaining a target composition by adding a dissolved solution and kneading and adsorbing these is mentioned. The solvent used in this method is not particularly limited as long as it dissolves acarbose and does not dissolve the porous adsorbent, but water, ethanol, or one or more mixed solvents thereof are preferable. Moreover, the removal of a solvent may be a normal drying means, for example, a shelf type dryer (40C), a fluidized bed dryer (MP-01) and the like. Although the temperature at the time of drying is not specifically limited, It is preferable to dry at 60-70 degreeC.
本発明の錠剤は、上記の方法で製造した組成物を慣用の方法により打錠して行うことができる。例えば、上記の方法で製造した組成物を単発打錠機(菊水製作所製)、ロータリー打錠機(VIRGO−512)等の通常使用される装置で打錠することにより目的の錠剤を得る方法が挙げられる。この場合の錠剤の打錠圧は、錠剤の製造に際して支障のない程度であれば特に限定されないが、650〜2200kg/cm2、好ましくは1300〜1800kg/cm2であるのがよい。 The tablet of the present invention can be obtained by tableting the composition produced by the above method by a conventional method. For example, there is a method of obtaining a target tablet by tableting the composition produced by the above method with a commonly used apparatus such as a single tableting machine (manufactured by Kikusui Seisakusho) or a rotary tableting machine (VIRGO-512). Can be mentioned. The tableting pressure of the tablet in this case is not particularly limited as long as it does not hinder the production of the tablet, but it is 650 to 2200 kg / cm 2, preferably 1300 to 1800 kg / cm 2.
本発明の錠剤は服用に際して支障のない大きさであることが好ましく、錠剤の重量は90〜500mg、好ましくは120〜300mgであるのがよく、大きさは直径5〜12mm、好ましくは6〜10mm、その厚さは3.0〜4.5mm、好ましくは3.1〜4.2mmであるのがよい。また、本発明の錠剤の硬度は、錠剤の取扱い、錠剤の崩壊性に支障のない程度であることが好ましく、35〜300N、好ましくは40〜150Nであるのがよい。 It is preferable that the tablet of the present invention has a size that does not hinder the administration, the tablet weight is 90 to 500 mg, preferably 120 to 300 mg, and the size is 5 to 12 mm in diameter, preferably 6 to 10 mm. The thickness is 3.0 to 4.5 mm, preferably 3.1 to 4.2 mm. Further, the hardness of the tablet of the present invention is preferably such that the handling of the tablet and the disintegration property of the tablet are not hindered, and it is preferably 35 to 300N, preferably 40 to 150N.
本発明の錠剤は、必要に応じて、賦形剤、結合剤、崩壊剤、滑沢剤、溶解補助剤などを含有することができる。例えば、トウモロコシデンプンなどのデンプン類、乳糖、白糖、マンニトール、キシリトール、エリスリトール、ソルビトール、マルチトール、クエン酸カルシウム、リン酸カルシウム、結晶セルロース、炭酸マグネシウム、炭酸カルシウム、メタケイ酸アルミン酸マグネシウム等の賦形剤;ショ糖、ゼラチン、アラビアゴム末、メチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ポリエチレングリコール、カルボキシメチルセルロース、結晶セルロース・カルボキシメチルセルロースナトリウム、デキストリン、プルラン、トラガント、アルギン酸ナトリウム、アルファー化デンプン等の結合剤;カルメロースナトリウム、クロスカルメロースナトリウム、カルメロースカルシウム、カルメロース、低置換度ヒドロキシプロピルセルロース、架橋カルメロースナトリウム、架橋ポリビニルピロリドン等の崩壊剤;ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク、軽質無水ケイ酸、含水二酸化ケイ素、ショ糖脂肪酸エステル、硬化油等の滑沢剤;グリセリン脂肪酸エステル、ソルビタン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンアルキルエーテル、ラウリル硫酸ナトリウム、ポリオキシエチレンポリオキシプロピレングリコール等の溶解補助剤;その他、香料、色素および矯味剤等が挙げられる。 The tablet of this invention can contain an excipient | filler, a binder, a disintegrating agent, a lubricant agent, a solubilizing agent, etc. as needed. For example, excipients such as starches such as corn starch, lactose, sucrose, mannitol, xylitol, erythritol, sorbitol, maltitol, calcium citrate, calcium phosphate, crystalline cellulose, magnesium carbonate, calcium carbonate, magnesium aluminate metasilicate; Sucrose, gelatin, gum arabic powder, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol, carboxymethylcellulose, crystalline cellulose / sodium carboxymethylcellulose, dextrin, pullulan, tragacanth, sodium alginate, pregelatinized starch, etc. Agents: Carmellose sodium, croscarmellose sodium, carmellose Disintegrating agents such as calcium, carmellose, low-substituted hydroxypropylcellulose, crosslinked carmellose sodium, crosslinked polyvinylpyrrolidone; magnesium stearate, calcium stearate, talc, light anhydrous silicic acid, hydrous silicon dioxide, sucrose fatty acid ester, hydrogenated oil, etc. Lubricants such as glycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, sodium lauryl sulfate, polyoxyethylene polyoxypropylene glycol, etc .; , Fragrances, pigments and flavoring agents.
以下に本発明を実施例により詳細に説明するが、本発明の範囲は下記の実施例に限定されることはない。 EXAMPLES The present invention will be described in detail below with reference to examples, but the scope of the present invention is not limited to the following examples.
〔実施例1〜6:アカルボースを本発明で使用する多孔性吸着剤、又はその多孔性吸着剤と無水リン酸水素カルシウムの混合物に吸着させて錠剤化する場合〕
表1に示す処方に基づき、以下の方法で錠剤を製造した。
[Examples 1 to 6: When acarbose is adsorbed on a porous adsorbent used in the present invention or a mixture of the porous adsorbent and anhydrous calcium hydrogen phosphate to form tablets]
Based on the formulation shown in Table 1, tablets were produced by the following method.
(1)表1に示す処方で、メタケイ酸アルミン酸マグネシウム〔ノイシリンUS2(比表面積:300m2/g):富士化学株式会社〕、軽質無水ケイ酸〔アドソリダー101(比表面積:300m2/g):フロイント産業株式会社〕、含水二酸化ケイ素〔カープレックス#67(比表面積:429m2/g)、カープレックス#80(比表面積:193m2/g):塩野義製薬株式会社〕、無水リン酸水素カルシウム〔フジカリン(比表面積:40m2/g):富士化学株式会社〕を乳鉢で混合する。
(2)アカルボースを精製水に溶解し、上記(1)と練合し、吸着させる。
(3)上記(2)の吸着末をミニジェットオーブンを用いて、60℃で乾燥する。
(4)乾燥後、整粒(22号篩)し、結晶セルロース、カルメロースカルシウムを加え、ビニール袋内で混合する。
(5)上記(4)に軽質無水ケイ酸及びステアリン酸マグネシウムを加えて混合した後、直径7mm、R面の杵を用いて単発打錠機(菊水製作所製)で打錠し、重量135mg、厚さ3.2mmの錠剤を得る。
(1) Magnesium aluminate metasilicate [Neusilin US2 (specific surface area: 300 m 2 / g): Fuji Chemical Co., Ltd.], light anhydrous silicic acid [Adsolider 101 (specific surface area: 300 m 2 / g): Freund Sangyo Co., Ltd.], hydrous silicon dioxide [Carplex # 67 (specific surface area: 429 m2 / g), Carplex # 80 (specific surface area: 193 m2 / g): Shionogi Pharmaceutical Co., Ltd.], anhydrous calcium hydrogen phosphate [Fujicalin ( Specific surface area: 40 m <2> / g): Fuji Chemical Co., Ltd.] is mixed in a mortar.
(2) Acarbose is dissolved in purified water, kneaded with (1) above and adsorbed.
(3) The adsorption powder of (2) is dried at 60 ° C. using a mini jet oven.
(4) After drying, the mixture is sized (No. 22 sieve), added with crystalline cellulose and carmellose calcium, and mixed in a plastic bag.
(5) After adding and mixing light anhydrous silicic acid and magnesium stearate to (4) above, tableting is performed with a single tableting machine (manufactured by Kikusui Seisakusho) using a 7 mm diameter, R-side punch, and the weight is 135 mg. A tablet with a thickness of 3.2 mm is obtained.
〔比較例1〜3:アカルボースを吸着剤に吸着せずに錠剤化する場合〕
表2に示す処方に基づき、以下の方法で錠剤を製造した。
[Comparative Examples 1-3: When acarbose is tableted without adsorbing to the adsorbent]
Based on the formulation shown in Table 2, tablets were produced by the following method.
(1)表2に示す処方で、アカルボース、トウモロコシデンプン(比表面積:0.4m2/g)、メタケイ酸アルミン酸マグネシウム(ノイシリンUS2:富士化学株式会社)、無水リン酸水素カルシウム(フジカリン:富士化学株式会社)、結晶セルロース(比表面積:1.1m2/g)をビニール袋内で混合する。
(2)さらに、軽質無水ケイ酸及びステアリン酸マグネシウムを加えて混合した後、直径7mm、R面の杵を用いて単発打錠機(菊水製作所製)で打錠し、重量135mg、厚さ3.2mmの錠剤を得る。
(1) In the formulation shown in Table 2, acarbose, corn starch (specific surface area: 0.4 m 2 / g), magnesium aluminate metasilicate (Neusilin US2: Fuji Chemical Co., Ltd.), anhydrous calcium hydrogen phosphate (Fujicalin: Fuji Chemical) Co., Ltd.) and crystalline cellulose (specific surface area: 1.1 m2 / g) are mixed in a plastic bag.
(2) Further, light anhydrous silicic acid and magnesium stearate were added and mixed, and then tableted with a single tableting machine (manufactured by Kikusui Seisakusho) using a 7 mm diameter, R-face punch, weight 135 mg, thickness 3 Obtain 2 mm tablets.
〔比較例4:アカルボースを無水リン酸水素カルシウムに吸着〕
表2に示す処方に基づき、以下の方法で錠剤を製造した。
[Comparative Example 4: Adsorption of acarbose on anhydrous calcium hydrogen phosphate]
Based on the formulation shown in Table 2, tablets were produced by the following method.
表2に示す処方で、アカルボースを精製水に溶解し、それを無水リン酸水素カルシウム〔フジカリン(比表面積:40m2/g):富士化学株式会社〕と練合し、吸着させたが、造粒物がケーキングを起こしたため、これ以上製造できなかった。 In the formulation shown in Table 2, acarbose was dissolved in purified water and kneaded with anhydrous calcium hydrogen phosphate [Fujicalin (specific surface area: 40 m 2 / g): Fuji Chemical Co., Ltd.] and adsorbed. Since the product caused caking, it could not be produced any more.
〔試験例1〕
実施例1〜6で得られた錠剤と比較例1〜3で得られた錠剤を、温度25℃、相対湿度75%の条件下で1週間又は2週間無包装の状態で放置し、錠剤の色調、容器への付着について観測した。錠剤の色調は分光式色差計(SE−2000)を用いて測定し、容器への付着については、目視により観察した。
[Test Example 1]
The tablets obtained in Examples 1 to 6 and the tablets obtained in Comparative Examples 1 to 3 were left unpacked for 1 week or 2 weeks under the conditions of a temperature of 25 ° C. and a relative humidity of 75%. The color tone and adhesion to the container were observed. The color tone of the tablet was measured using a spectroscopic color difference meter (SE-2000), and the adhesion to the container was visually observed.
表1、表2の配合比率で得られた錠剤の色調、容器への付着の観測結果を表3に示した。表中の記号については、JIS規格において離間比較ではほとんど気づかない色差で、一般的には同じ色だと思われているレベルであるA級許容差に適合するもの若しくはそれ以上のものについては○、適合しないものについては×、を記載した。 Table 3 shows the color tone of the tablets obtained at the blending ratios in Tables 1 and 2 and the observation results of adhesion to the container. The symbols in the table are color differences that are hardly noticed in the JIS standard in the distance comparison, and those that meet or exceed Class A tolerance, which is generally considered to be the same color. In the case of non-conformity, x was described.
表3に示すとおり、本発明で使用する多孔性吸着剤、又はその多孔性吸着剤と無水リン酸水素カルシウムの混合物にアカルボースを吸着させた実施例1〜6は、吸着させていない比較例1〜3に比べ錠剤の色調変化が改善されており、容器への付着もないことが認められた。また、比表面積が40m2/gである無水リン酸水素カルシウムにアカルボースを吸着させる比較例4については、服用するのに支障がない大きさの錠剤を製造すると、吸着が不十分となり、ケーキングを起こし製造することができなかった。この結果より、本発明のアカルボース含有錠剤は、高湿度条件下において製剤の安定性が優れていることが確認された。 As shown in Table 3, Examples 1 to 6 in which acarbose was adsorbed to the porous adsorbent used in the present invention or a mixture of the porous adsorbent and anhydrous calcium hydrogen phosphate were not Comparative Examples 1 It was confirmed that the color change of the tablet was improved as compared with ˜3, and there was no adhesion to the container. In Comparative Example 4 in which acarbose is adsorbed to anhydrous calcium hydrogen phosphate having a specific surface area of 40 m 2 / g, if a tablet having a size that does not hinder the use is produced, the adsorption becomes insufficient and caking occurs. Could not be manufactured. From this result, it was confirmed that the acarbose-containing tablet of the present invention is excellent in the stability of the preparation under high humidity conditions.
〔試験例2〕
実施例1〜6で得られた錠剤について、SHLEUNIGER硬度計を用いて錠剤硬度の測定を行った。
[Test Example 2]
About the tablet obtained in Examples 1-6, the tablet hardness was measured using the SHLEUNIGER hardness meter.
実施例1〜6で得られた錠剤の硬度測定結果を表4に示した。 Table 4 shows the hardness measurement results of the tablets obtained in Examples 1 to 6.
いずれの錠剤も、取り扱い上問題のない錠剤硬度を有するが、実施例5〜6の様に、本発明で使用する多孔性吸着剤と無水リン酸水素カルシウムの混合物にアカルボースを吸着させた場合、その混合比を調節することにより、所望の錠剤硬度を得ることができた。 Each tablet has a tablet hardness with no problem in handling, but as in Examples 5 to 6, when acarbose was adsorbed to the mixture of the porous adsorbent used in the present invention and anhydrous calcium hydrogen phosphate, The desired tablet hardness could be obtained by adjusting the mixing ratio.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009033818A JP5491040B2 (en) | 2008-02-27 | 2009-02-17 | Tablets containing acarbose |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008046912 | 2008-02-27 | ||
JP2008046912 | 2008-02-27 | ||
JP2009033818A JP5491040B2 (en) | 2008-02-27 | 2009-02-17 | Tablets containing acarbose |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009227658A JP2009227658A (en) | 2009-10-08 |
JP5491040B2 true JP5491040B2 (en) | 2014-05-14 |
Family
ID=41243466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009033818A Active JP5491040B2 (en) | 2008-02-27 | 2009-02-17 | Tablets containing acarbose |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5491040B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6340325B2 (en) * | 2014-12-29 | 2018-06-06 | 沢井製薬株式会社 | Naphtopidil-containing orally disintegrating tablets |
JP7200657B2 (en) * | 2018-12-20 | 2023-01-10 | 東洋インキScホールディングス株式会社 | Methacrylate monomers, polymers, resin compositions, laminates and moldings |
CN116236451B (en) * | 2023-04-18 | 2024-04-19 | 淄博市中心医院 | Acarbose tablet, preparation method and application |
CN116763752B (en) * | 2023-08-24 | 2023-11-17 | 北京福元医药股份有限公司 | Acarbose tablet and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61186313A (en) * | 1985-02-12 | 1986-08-20 | Dainippon Pharmaceut Co Ltd | Valproate sodium preparation |
JPH0812569A (en) * | 1994-06-24 | 1996-01-16 | Takeda Chem Ind Ltd | Solid substance adsorbing carnitine chloride thereon |
JPH09169639A (en) * | 1995-12-20 | 1997-06-30 | Taisho Yakuhin Kogyo Kk | Stable teprenone-containing solid preparation and its production |
JP4027535B2 (en) * | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Powder containing fat-soluble drug |
WO2003004001A1 (en) * | 2001-07-06 | 2003-01-16 | Lifecycle Pharma A/S | Controlled agglomeration |
-
2009
- 2009-02-17 JP JP2009033818A patent/JP5491040B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009227658A (en) | 2009-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5409382B2 (en) | Orally disintegrating tablets | |
JP4868695B2 (en) | Oral preparation with good disintegration | |
RU2639473C2 (en) | Oral pharmaceutical composition | |
JP2004531537A (en) | Process for producing low-dose pharmaceutical compositions with uniform drug distribution and efficacy | |
JP5491040B2 (en) | Tablets containing acarbose | |
JP2022033292A (en) | Pharmaceutical tablets containing levocarnitine | |
EP2698159A1 (en) | Pitavastatin-containing preparation and method for producing same | |
JP5721093B2 (en) | Disintegrating tablet | |
JP5318400B2 (en) | Tablets containing levofloxacin | |
JP2010202579A (en) | Acarbose-containing disintegrating preparation in oral cavity | |
JP5844574B2 (en) | Stabilized drug composition containing pitavastatin | |
WO2012057103A1 (en) | Pharmaceutical composition | |
JP4860486B2 (en) | Orally disintegrating solid preparation containing povidone iodine | |
JP4329947B1 (en) | Tablets for internal use | |
CN101405004A (en) | Novel film-coated tablet | |
JP2007332063A (en) | Povidone-iodine-containing intraoral disintegration type solid preparation | |
WO2020111089A1 (en) | Pharmaceutical composition | |
JP6114573B2 (en) | Solid formulation containing loxoprofen sodium and antacid | |
JP2020180101A (en) | Method for Producing Levetiracetam-Containing Pharmaceutical Composition | |
WO2020122244A1 (en) | Tablet and method for producing same | |
UA79567C2 (en) | Orodispersible pharmaceutical composition of antithrombolic compound | |
JP5282644B2 (en) | Tablets for internal use | |
JP2003137778A (en) | Pharmaceutical composition and medicine | |
KR20170001786A (en) | Preparation method for pharmaceutical composition comprising Pelargonium sidoides extracts | |
JP6283314B2 (en) | Anagliptin-containing solid preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5491040 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |